Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Pfizer

The Daily Biotech Pulse: Setback For NRx Pharma's COVID Study, Fast Track Tag For Pfizer's NASH Combo Therapy, Reata's Ataxia Drug In FDA Review

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

How important is the COVID-19 booster shot for 5-to-11-year-olds? 5 questions answered

COVID-19 case numbers are rising again in the U.S. – including among children. In mid-May 2022, the Food and Drug Administration authorized a booster shot of the COVID-19 vaccine for U.S. children ages 5 to 11, and the Centers for Disease Control and Prevention followed by recommending a booster shot…

The Conversation

Pfizer Offers to Sell Medicines at Cost to Poorest Countries

US pharmaceutical giant Pfizer on Wednesday said it would sell its patented drugs on a not-for-profit basis to the world's poorest countries, as part of a new initiative announced at the World Economic Forum in Davos. "The time is now to begin closing this gap" between people with access to…

Asharq Al-Awsat

From analysis to the latest developments in health,
read the most diverse news in one place.

Health brands' reputation rise after pandemic

A renewed focus on health and wellness has been a boon to the reputations of health care companies, according to new rankings from the annual Axios/Harris Poll 100.

Axios

Morning Brief: Top Financial Stories Dominating on Wednesday, May 25

Reuters Ford To Pay $19.2M In Multi-State Settlement For False Advertising Claims

Benzinga

Pfizer To Sell 23 Patented Drugs, Vaccines At Lower Prices To Poorer Countries

Pfizer Inc (NYSE:PFE) will sell over 20 patent-protected drugs and vaccines at not-for-profit prices to 45 of the world's poorest countries. Under the program, Pfizer will begin shipping the medicines first to Ghana, Malawi, Rwanda, Senegal, and Uganda before the end of this year, Chief Executive Albert Bourla said in an interview. This will…

Benzinga

Pfizer to offer all its drugs not-for-profit to 45 lower-income countries

Company launches ‘healthier world’ accord in Davos and speaks to other pharma firms about similar steps

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Davos updates | Pfizer offers low-cost drugs to poor nations

Pfizer says it will provide nearly two dozen products, including its top-selling COVID-19 vaccine and treatment, at not-for-profit prices in some of the world’s poorest countries

The Independent UK

Cambodia, Laos to benefit as Pfizer slashes drug prices for poorest nations

Pfizer Inc plans to sell its entire portfolio of brand-name drugs at cost in as many as 45 lower-income countries, including Cambodia and Laos, one of the most comprehensive and ambitious drug-access programmes ever announced by a large pharmaceutical manufacturer.

Bangkok Post

Pfizer to sell all its patented drugs at nonprofit price in low-income countries

Pfizer Inc will make all of its patented medicines including COVID-19 treatment Paxlovid and big-selling breast cancer drug Ibrance available at a not-for-profit price to 45 of the world's poorest countries, the drugmaker said on Wednesday.

Reuters

Pfizer to offer low-cost medicines, vaccines to poor nations

Pfizer says it will provide nearly two dozen products at not-for-profit prices in some of the world’s poorest countries

The Independent UK

Germany's vaccine panel says one COVID shot enough for children

Germany's vaccine advisory panel on Tuesday said one COVID-19 shot was enough for healthy five- to 11-year-olds because most of them had already undergone an infection, maintaining its cautious approach.

Reuters

Pfizer's Ulcerative Colitis Candidate Shows Remission In Over 30% Of Patients In Pivotal Studies

Pfizer Inc (NYSE:PFE) has announced detailed results from two pivotal studies from ELEVATE UC Phase 3 program evaluating etrasimod for active ulcerative colitis (UC). The drug, etrasimod, was Pfizer's key asset in its $6.7 billion deal for Arena Pharmaceuticals last year. UC is an inflammatory bowel disease that affects around 3.8 million people in North…

Benzinga

What happened to the AstraZeneca vaccine? How blood clot scares tarnished its reputation

While the AZ./Oxford vaccine has all but vanished from richer countries, it has continued to be rolled out elsewhere

Wales Online

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

China's bet on homegrown mRNA vaccines holds back nation

China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19

The Hindu

Morning Digest | Quad leaders meet in Tokyo at 2nd in-person summit; India to be the leader of green hydrogen, says Puri in Davos, and more

A select list of stories to read before you start your day

The Independent UK

What's next for COVID-19 vaccines for youngest US children

Parents hoping to get their youngest children vaccinated against COVID-19 have some encouraging news

The Conversation

What happened to the AstraZeneca vaccine? Now rare in rich countries, it’s still saving lives around the world

The AstraZeneca vaccine, developed in partnership with the University of Oxford, was one of the first vaccines available for use in the UK and around the world during the COVID pandemic.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Biohaven's Neurological Disease Candidate Flunks In Late-Stage Study

Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) has announced topline Phase 3 results of troriluzole in patients with spinocerebellar ataxia (SCA). The primary endpoint measured the change in the severity of symptoms among patients from the baseline to week 48 of treatment. It did not reach statistical significance in the overall SCA population as…

Tribune News Service

Pfizer COVID shot seems protective for children under 5 in early data

Pfizer Inc. and BioNTech SE said their COVID-19 vaccine was highly effective and prompted a strong immune response in children under age 5, based on early results from a trial that is likely to pave the way for infants and toddlers to finally get immunized.

Evening Standard

Covid vaccine: Pfizer says three doses enough to protect children under 5

Three doses of Pfizer’s Covid-19 vaccine will offer strong protection for children younger than 5, the company announced on Monday.

WEKU

If Pfizer's data pans out, when will little kids get the COVID-19 vaccine?

Pfizer plans to submit new data to the Food and Drug Administration this week, bringing families with young children one step closer to a long-awaited vaccine.

Reuters

Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

The Independent UK

Pfizer says 3 COVID shots protect children under 5

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week

Axios

Pfizer says COVID vaccine more than 80% effective in kids under 5

Pfizer reported three doses of its vaccine in kids under five produced a strong immune response and was safe.

1 … 50 51 52 53

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.